Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
[Cognitive performance and quality of life in multiple sclerosis in Gipuzkoa].
The microglial sensome revealed by direct RNA sequencing.
Clinically isolated syndromes and the relationship to multiple sclerosis.
Defining high, medium and low impact prognostic factors for developing multiple sclerosis.
Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis.
B-57The Temporal Onset of Cognitive Fatigue in Multiple Sclerosis.
Progressive resistance therapy is not the best way to rehabilitate deficits due to multiple sclerosis: No.
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning.
Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-Aquaporin 4 antibodies.
Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod.
Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis.
A new prevalence study of multiple sclerosis in Orkney, Shetland and Aberdeen city.
Magnetic Resonance Imaging of Optic Neuritis in Patients With Neuromyelitis Optica Versus Multiple Sclerosis.
Disease-modifying therapies in Chinese children with multiple sclerosis.
Wnt Signaling in the Pathogenesis of Multiple Sclerosis-Associated Chronic Pain.
Laquinimod Halted MS Disability But Not Relapses
Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72.
Significance of Virchow-Robin Spaces in Patients Newly Diagnosed with Multiple Sclerosis: A Case-Control Study in an Arab Population.
Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis?
Sativex(®) in multiple sclerosis spasticity: a cost-effectiveness model.
Eosinophilic Fasciitis Occurring under Treatment with Natalizumab for Multiple Sclerosis.
Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases.
Submembranous cytoskeletons stabilize nodes of Ranvier.
Cystoid macular edema associated with fingolimod use for multiple sclerosis.
Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS.
Pages
« first
‹ previous
…
131
132
133
134
135
136
137
138
139
…
next ›
last »